69 related articles for article (PubMed ID: 38698351)
1. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.
D'Amico F; Peyrin-Biroulet L; Danese S
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892780
[No Abstract] [Full Text] [Related]
2. A practical guide about biosimilar data for health care providers treating inflammatory diseases.
Markenson J; Alvarez DF; Jacobs I; Kirchhoff C
Biologics; 2017; 11():13-21. PubMed ID: 28280299
[TBL] [Abstract][Full Text] [Related]
3. Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine.
Prasanna Kumar KM; Chowdhury S; Bantwal G; Unnikrishnan AG; Kalra S; Aggarwal S; Singh AK; Pandit K; Shukla R; Vishwanathan V; Khobragade K; Sarda PS
Cureus; 2024 May; 16(5):e60983. PubMed ID: 38910730
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry.
Martínez-Vidal MP; Fernández-Carballido C; Otero-Varela L; Manero Ruiz FJ; Pérez-Vera Y; Manrique Arija S; Campos Fernández C; Jovaní V; Expósito L; Álvarez Lario B; García-González J; Sánchez-Alonso F; Castrejón I
J Rheumatol; 2024 Jul; ():. PubMed ID: 38825358
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians.
Tano M; Paubel P; Ribault M; Degrassat-Théas A
Pharmacoecon Open; 2024 Jul; ():. PubMed ID: 38956007
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.
Subramanian J; Cavenagh J; Desai B; Jacobs I
Cancer Manag Res; 2017; 9():131-140. PubMed ID: 28479860
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates.
Costin J; Mouslim MC; Socal MP; Trujillo A
Pharmacoecon Open; 2024 Jan; 8(1):115-118. PubMed ID: 37921963
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the situation of pharmaceutical care for patients with immune-mediated inflammatory diseases before and after the COVID-19 pandemic.
López Sánchez P; Palanques Pastor T; Ibarra Barrueta O; Ramírez Herráiz E; Casellas Gibert M; Monte Boquet E
Farm Hosp; 2024 Jun; ():. PubMed ID: 38906719
[TBL] [Abstract][Full Text] [Related]
9. Knowledge of biological therapy for patients with immune-mediated diseases. BIOINFO Study.
Seguí-Solanes C; Estrada L; Ramírez Herráiz E; Ruiz-García S; Palanques-Pastor T; Merino Bohórquez V; Capilla Montes C; Borras-Blasco J
Farm Hosp; 2024 Jun; ():. PubMed ID: 38845272
[TBL] [Abstract][Full Text] [Related]
10. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.
Kearsley-Fleet L; Rokad A; Tsoi MF; Zhao SS; Lunt M; Watson KD; ; Hyrich KL
Rheumatology (Oxford); 2023 Dec; 62(12):3849-3857. PubMed ID: 36943379
[TBL] [Abstract][Full Text] [Related]
11. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars and access to biologic therapy in immune-mediated diseases.
Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
Expert Opin Biol Ther; 2024 May; ():1-7. PubMed ID: 38698351
[TBL] [Abstract][Full Text] [Related]
13. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
14. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
